Studies Available
| Indication |
Treatment |
Allocation |
Freq.
of visits |
| All cancers |
Combination masitinib/vinblastin |
Single arm study |
Every week |
| All cancers |
Combination masitinib/gemcitabin |
Single arm study |
Every week |
| Splenic hemangiosarcoma (dogs naïve of treatment) |
Masitinib Doxorubicin Combination masitinib/doxorubicin |
Automatic randomization |
Every 3 weeks |
| T cell lymphoma (dogs naïve of treatment) |
Masitinib Doxorubicin Combination masitinib/doxorubicin |
Automatic randomization |
Every 3 weeks |
| Melanoma (dogs naïve of treatment) |
Combination masitinib/doxorubicin Vaccine |
Automatic randomization |
Every 3 weeks
Every 2 weeks |
| Melanoma expressing mutated c-kit (dogs naïve of treatment) |
Masitinib Vaccine |
Automatic randomization |
Every 2 weeks |
Eligibility Requirements
• Main exclusion criteria are: Dogs less than 6 months of age or weighing less than 3.5 kg (7.7 lb), with cardiac insufficiency, evidence of gastric bleeding, other serious disease or prior history of kidney disease.
Study Objective
Masitinib is a registered therapy in Europe to treat unresectable Mast Cell Tumors in dogs. Masitinib is a Tyrosine Kinase Inhibitor that selectively inhibits c-kit, PDGFr and Lyn. Masitinib strongly inhibits the proliferation of T-cell lymphoma cell lines (through PDGFr inhibition). In vitro, Masitinib strongly sensitizes several cancer cell lines to chemotherapy (including hemangiosarcoma, T cell lymphoma and melanoma cancer cell lines).
Compensation
The studies are partially funded. For more details, please contact Maria Salas or Dr. Gerald Post at 203-838-6626
Location of Trial
Norwalk, CT
More information - Please contact Maria Salas or Dr. Gerald Post at 203-838-6626
